Avaliação da atividade do Novaluron, sobre Boophilus microplus (Canestrini) em bovinos de corte naturalmente infestados

• Ano de defesa: 2009
• Autor(a) principal: Souza, Gladstone Santos de
• Orientador(a): Aquino, Gilberto Lucio Benedito de
• Banca de defesa: Pérez, Caridad Noda , Martins, Paula Melo
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Pontifícia Universidade Católica de Goiás
• Programa de Pós-Graduação: Programa de Pós-Graduação STRICTO SENSU em Tecnologia Farmacêutica
• Departamento: Ciências da Saúde
• País: BR
• Palavras-chave em Português: Bovino de corte; carrapato bovino; Boophilus microplus; benzoilfeniluréia; fluazuron; novaluron; clarion
• Palavras-chave em Inglês: Cut bovine; bovine tick; Boophilus microplus; benzoylphenyl ureas; fluazuron; novaluron; clarion
• Área do conhecimento CNPq: CNPQ::CIENCIAS DA SAUDE::FARMACIA
• Link de acesso: http://localhost:8080/tede/handle/tede/2133

The bovine tick is the ectoparasite that causes the greatest prejudice to Brazilian farming and cattle raising, and its control is realized basically through chemical products, which are losing effectiveness over time. This work aimed to evaluate the efficacy of a transdermal formulation, developed by the laboratory Clarion Biociências Ltd. It contains the medicine novaluron, against the tick Boophilus microplus in naturally infested animals. Animals used in the experiment were kept in a pasture with Brachiaria brizantha ascendancy, water; animal food and mineral salt were supplied ad libitum. The formulation containing novaluron was tested in five different dosages: 5.0; 2.5; 1.66; 1.25 and 1.0mg/kg of live weight in a single dose compared to a placebo group and control. The weight of the animals of the experiment varied from 290 to 339kg. Only the dosages of 5.0 and 2.5mg/kg attended the least requisites. The evaluation of the plasmatic profiles of the dosages of 2.50 and 5.00mg/kg of novaluron, presented the following results respectively: concentration peak (Cmax) was 378 and 396ng/mL; the time for obtainment of the concentration peak (Tmax) was 4 days for both dosages and the area on the plasmatic concentration curve(ASC) > 100ng was 28 and 42 days. Based on the results of efficacy and analysis of the plasmatic profile it was concluded that the 2.5mg/kg dosage presented a better relation cost/ benefit. Afterwards it was realized the efficacy of the formulation of novaluron 5% in the dosage of 2.5mg/kg live weight in a single dose comparatively to the commercial product fluazuron, formulation containing 2.5% of fluazuron in the dosage of 2.5mg/kg in a single dose compared to the group control. The results for the two products were alike. It was concluded that a formulation containing 5% of novaluron in the 2.5mg/kg dosage owns the safety requisites, efficacy and economic which make feasible complementary studies for register and commercialization.